Morepen Laboratories Ltd.
BSE: 500288 | Sector: Health care |
NSE: MOREPENLAB | ISIN Code: INE083A01026 |
BSE 00:00 | 23 Mar | 25.62 |
0.49 (1.95%) |
OPEN
25.13 |
HIGH
26.84 |
LOW
25.07 |
NSE 00:00 | 23 Mar | 25.60 |
0.50 (1.99%) |
OPEN
25.20 |
HIGH
26.90 |
LOW
25.05 |
OPEN | 25.13 |
PREVIOUS CLOSE | 25.13 |
VOLUME | 1232882 |
52-Week high | 54.80 |
52-Week low | 23.65 |
P/E | 26.14 |
Mkt Cap.(Rs cr) | 1,310 |
Buy Price | 0.00 |
Buy Qty | 0.00 |
Sell Price | 0.00 |
Sell Qty | 0.00 |
Morepen Laboratories Ltd. (MOREPENLAB) - News Sector
-
Multiple triggers likely to help Zydus to continue with its outperformance
11.14 pm | 23 Mar 2023 | Business Standard
New launches in the US, market share gains and steady domestic growth are positives
-
Fight over control of Hikal: Hiremath, family move HC against Baba Kalyani
10.40 pm | 23 Mar 2023 | Business Standard
Hikal said it did not expect any financial implications arising due to compensation, penalty, etc, due to the suit
-
India's e-comm mkt to grow from $83 bn in 2022 to $185 bn in 2026: Report
5.03 pm | 23 Mar 2023 | Business Standard
UPI driving consumers away from cash and helping financial inclusion, it says
-
Glenmark gets USFDA nod to market generic medication to treat schizophrenia
11.53 am | 20 Mar 2023 | Press Trust of India
Glenmark Pharmaceuticals on Monday said it has received approval from the US health regulator to market a generic product used to treat schizophrenia ...
-
India was world's No. 1 in handling Covid: Apollo Hospitals founder
10.54 pm | 19 Mar 2023 | Business Standard
In a Q&A, Prathap Chandra Reddy talks about the need to focus on medical tourism and medical education to meet the demand of 18 million professionals ...
-
Eris down 4% in 2 days post acquisition of 9 derma brands from Dr Reddy's
10.47 am | 17 Mar 2023 | Business Standard
Eris Life said that the transaction would help augment and expand cosmetic dermatology business of the company through their product offerings
-
Eris down 4% in 2 days post acquisition of 9 derma brands from Dr Reddy's
10.47 am | 17 Mar 2023 | Business Standard
Eris Life said that the transaction would help augment and expand cosmetic dermatology business of the company through their product offerings
-
Eris Lifesciences buys dermatology brands from Dr Reddy's for Rs 275 crore
11.30 pm | 16 Mar 2023 | Business Standard
In January Eris had bought some derma brands from Glenmark Pharma as well
-
RIL, Mphasis: 45 stocks hit fresh 52-week lows; charts show more pain ahead
11.35 am | 15 Mar 2023 | Business Standard
The heavy-weight Reliance Industries has broken critical support of Rs 2,300, raising concerns about the future drawdown. In addition, the formation r...
-
RIL, Mphasis: 45 stocks hit fresh 52-week lows; charts show more pain ahead
11.35 am | 15 Mar 2023 | Business Standard
The heavy-weight Reliance Industries has broken critical support of Rs 2,300, raising concerns about the future drawdown. In addition, the formation r...
-
RIL, Mphasis: 45 stocks hit fresh 52-week lows; charts show more pain ahead
11.35 am | 15 Mar 2023 | Business Standard
The heavy-weight Reliance Industries has broken critical support of Rs 2,300, raising concerns about the future drawdown. In addition, the formation r...
-
RIL, Mphasis: 45 stocks hit fresh 52-week lows; charts show more pain ahead
11.35 am | 15 Mar 2023 | Business Standard
The heavy-weight Reliance Industries has broken critical support of Rs 2,300, raising concerns about the future drawdown. In addition, the formation r...
-
Nifty Pharma index hits 2-year low; Cipla, Divis, Laurus Labs at 52-wk lows
2.25 pm | 14 Mar 2023 | Business Standard
Analysts said the pace of US FDA inspections has again picked-up in the last few months post Covid, and they have seen increased incidents with 483 ob...
-
Nifty Pharma index hits 2-year low; Cipla, Divis, Laurus Labs at 52-wk lows
2.25 pm | 14 Mar 2023 | Business Standard
Analysts said the pace of US FDA inspections has again picked-up in the last few months post Covid, and they have seen increased incidents with 483 ob...
-
Nifty Pharma index hits 2-year low; Cipla, Divis, Laurus Labs at 52-wk lows
2.25 pm | 14 Mar 2023 | Business Standard
Analysts said the pace of US FDA inspections has again picked-up in the last few months post Covid, and they have seen increased incidents with 483 ob...
-
Nifty Pharma index hits 2-year low; Cipla, Divis, Laurus Labs at 52-wk lows
2.25 pm | 14 Mar 2023 | Business Standard
Analysts said the pace of US FDA inspections has again picked-up in the last few months post Covid, and they have seen increased incidents with 483 ob...
-
Nifty Pharma index hits 2-year low; Cipla, Divis, Laurus Labs at 52-wk lows
2.25 pm | 14 Mar 2023 | Business Standard
Analysts said the pace of US FDA inspections has again picked-up in the last few months post Covid, and they have seen increased incidents with 483 ob...
-
Nifty Pharma index hits 2-year low; Cipla, Divis, Laurus Labs at 52-wk lows
2.25 pm | 14 Mar 2023 | Business Standard
Analysts said the pace of US FDA inspections has again picked-up in the last few months post Covid, and they have seen increased incidents with 483 ob...
-
Glenmark Pharma receives USFDA approval for generic antibiotic drug
2.19 pm | 14 Mar 2023 | Press Trust of India
Glenmark Pharmaceuticals on Tuesday said it has received approval from the US health regulator to market a generic antibiotic drug. The company has r...
-
NTPC, PFC: 5 F&O stocks see long OI build-up; Here's how to trade in them
11.26 am | 13 Mar 2023 | Business Standard
Build-up of long OI in general indicates that traders are expecting the price of the underlying stock or index to gain in the near-term.
Quick Links for Morepen Laboratories:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices